Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Average Recommendation of “Hold” from Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has earned an average recommendation of “Hold” from the ten ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $10.28.

Several equities research analysts have recently weighed in on the company. William Blair reissued a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Royal Bank of Canada reduced their price objective on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Wells Fargo & Company started coverage on shares of Maravai LifeSciences in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $10.00 target price on the stock. The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their target price for the stock from $7.00 to $4.25 in a research report on Thursday, December 5th. Finally, Robert W. Baird dropped their price objective on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th.

Maravai LifeSciences Stock Down 1.6 %

Maravai LifeSciences stock opened at $5.58 on Tuesday. The stock’s fifty day moving average is $6.47 and its two-hundred day moving average is $7.71. The stock has a market cap of $1.41 billion, a PE ratio of -3.40 and a beta of -0.08. Maravai LifeSciences has a 1-year low of $4.28 and a 1-year high of $11.56. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94.

Insider Buying and Selling at Maravai LifeSciences

In other news, insider Carl Hull purchased 175,000 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was acquired at an average price of $5.64 per share, with a total value of $987,000.00. Following the purchase, the insider now directly owns 175,000 shares of the company’s stock, valued at $987,000. This represents a ? increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.63% of the stock is owned by corporate insiders.

Institutional Trading of Maravai LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Maravai LifeSciences in the second quarter valued at $32,000. Blue Trust Inc. purchased a new position in Maravai LifeSciences during the second quarter worth approximately $44,000. Venturi Wealth Management LLC acquired a new position in Maravai LifeSciences in the third quarter valued at $47,000. Custom Index Systems LLC acquired a new stake in Maravai LifeSciences during the 3rd quarter worth approximately $97,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Maravai LifeSciences in the 3rd quarter valued at $105,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.